Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.
about
The Crossroads of Geriatric Cardiology and Cardio-OncologyA novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testingCardiomyocyte autophagy and cancer chemotherapy.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Cardiotoxic heart failure in breast cancer survivors: a concept analysis.The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method.Global longitudinal strain: a useful everyday measurement?Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity.DHA-mediated regulation of lung cancer cell migration is not directly associated with Gelsolin or Vimentin expression.Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.Chemo cured the cancer: what about the patient?Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
P2860
Q26778666-136E3884-600B-483E-AEC1-240F305A541EQ27311346-A4B0FBC3-C226-409C-AC5F-A5FBD3408F38Q33573823-BAACCF2A-830C-4D35-9840-7FEF520D68AEQ33658456-D60E7284-FED0-4CE2-B37D-872FA4164B3AQ36002576-B99EAD9E-C28C-4DAB-BE8A-306D5539A3EAQ36479962-DF550430-A2B6-49D2-9E79-5715D7390D6BQ37321045-194203FA-6DDC-4C25-B3EC-3503D46D82FBQ37361224-0AE47896-259E-4813-9DA1-A2946F5C50FCQ38640998-D9A7FF71-46EC-413F-8850-AA3792A6A628Q39784847-772B36A6-83B4-4E65-A7B5-0CD62B58ECC9Q40218182-88D59613-C934-4864-8209-8E86ADAB1D3FQ50504945-5F9D9CB8-75E6-465E-AE1A-8BC6792E3372Q55019544-A73270CB-EC94-48B7-B924-134D62F10B02Q56362782-38938C35-71E0-46D4-B261-DD57819EBE63
P2860
Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@ast
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@en
type
label
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@ast
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@en
prefLabel
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@ast
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@en
P2093
P2860
P356
P1476
Cardiotoxicity of cancer thera ...... ning, prevention, and therapy.
@en
P2093
Igal A Sebag
Jenna Berger
Richard J Sheppard
P2860
P356
10.3389/FPHAR.2013.00019
P577
2013-03-12T00:00:00Z